ATE266409T1 - Synergistische wirkung von glyburide und milrinone - Google Patents
Synergistische wirkung von glyburide und milrinoneInfo
- Publication number
- ATE266409T1 ATE266409T1 AT01303020T AT01303020T ATE266409T1 AT E266409 T1 ATE266409 T1 AT E266409T1 AT 01303020 T AT01303020 T AT 01303020T AT 01303020 T AT01303020 T AT 01303020T AT E266409 T1 ATE266409 T1 AT E266409T1
- Authority
- AT
- Austria
- Prior art keywords
- sulfonylurea
- diabetic
- channel blocker
- atp channel
- inhibitor
- Prior art date
Links
- 230000002195 synergetic effect Effects 0.000 title abstract 2
- 229960004580 glibenclamide Drugs 0.000 title 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 title 1
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 title 1
- 229960003574 milrinone Drugs 0.000 title 1
- 229940100389 Sulfonylurea Drugs 0.000 abstract 6
- BNYHRGTXRPWASY-UHFFFAOYSA-N nonylsulfonylurea Chemical compound CCCCCCCCCS(=O)(=O)NC(N)=O BNYHRGTXRPWASY-UHFFFAOYSA-N 0.000 abstract 6
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 abstract 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 4
- 102000001707 3',5'-Cyclic-AMP Phosphodiesterases Human genes 0.000 abstract 3
- 108010054479 3',5'-Cyclic-AMP Phosphodiesterases Proteins 0.000 abstract 3
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 abstract 3
- 208000002177 Cataract Diseases 0.000 abstract 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 2
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 2
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 2
- 206010022489 Insulin Resistance Diseases 0.000 abstract 2
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 2
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Paper (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19672800P | 2000-04-13 | 2000-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE266409T1 true ATE266409T1 (de) | 2004-05-15 |
Family
ID=22726606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01303020T ATE266409T1 (de) | 2000-04-13 | 2001-03-30 | Synergistische wirkung von glyburide und milrinone |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6610746B2 (de) |
| EP (1) | EP1145717B1 (de) |
| JP (1) | JP2001354568A (de) |
| AT (1) | ATE266409T1 (de) |
| BR (1) | BR0101461A (de) |
| CA (1) | CA2343850A1 (de) |
| DE (1) | DE60103203T2 (de) |
| DK (1) | DK1145717T3 (de) |
| ES (1) | ES2218338T3 (de) |
| MX (1) | MXPA01003853A (de) |
| PT (1) | PT1145717E (de) |
| TR (1) | TR200401145T4 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2809310B1 (fr) * | 2000-05-26 | 2004-02-13 | Centre Nat Rech Scient | Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant |
| CA2369967A1 (en) * | 2001-02-12 | 2002-08-12 | Joseph Anthony Cornicelli | Methods of treating nuclear factor-kappa b mediated diseases and disorders |
| SE0101980D0 (sv) * | 2001-06-01 | 2001-06-01 | Astrazeneca Ab | Pharmaceutical combination |
| SE0101981D0 (sv) * | 2001-06-01 | 2001-06-01 | Astrazeneca Ab | Pharmaceutical combination |
| DE60237696D1 (de) * | 2001-08-01 | 2010-10-28 | Univ Utah | Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a |
| US7105489B2 (en) * | 2002-01-22 | 2006-09-12 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
| GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| US8980952B2 (en) * | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
| DK2438913T3 (da) * | 2002-03-20 | 2020-06-22 | Univ Maryland | Ikke-selektiv kationkanal i neurale celler og forbindelser, der blokerer kanalen, til anvendelse i behandling af opsvulmning af hjernen |
| JPWO2003097064A1 (ja) * | 2002-05-17 | 2005-09-15 | 協和醗酵工業株式会社 | 糖尿病治療剤 |
| JP2006519229A (ja) | 2003-02-13 | 2006-08-24 | アルバート・アインシュタイン・カレッジ・オヴ・メディシン・オヴ・イェシヴァ・ユニヴァーシティ | 視床下部内の長鎖脂肪アシルＣｏＡレベルの変調による摂食量およびグルコース産生量の調節 |
| US7654375B2 (en) * | 2004-03-02 | 2010-02-02 | Ntn Corporation | Rotation transmission device |
| RU2387663C2 (ru) * | 2004-03-04 | 2010-04-27 | Киссеи Фармасьютикал Ко., Лтд. | Конденсированные гетероциклические производные, содержащие их медицинские композиции и их медицинское применение |
| EP1755581B1 (de) * | 2004-04-23 | 2015-07-15 | Northern Sydney Local Health District | Verfahren und zusammensetzungen zur behandlung von myokardialen erkrankungen |
| AU2005287090A1 (en) * | 2004-09-18 | 2006-03-30 | Department Of Veterans Affairs | Therapeutic agents targeting the NCca-ATP channel and methods of use thereof |
| ATE486606T1 (de) * | 2004-09-18 | 2010-11-15 | Univ Maryland | Therapeutische mittel zum targeting des ncca-atp- kanals und verwendungsverfahren dafür |
| WO2006041922A2 (en) * | 2004-10-08 | 2006-04-20 | Dara Biosciences, Inc. | Agents and methods for administration to the central nervous system |
| US20070026079A1 (en) * | 2005-02-14 | 2007-02-01 | Louis Herlands | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels |
| US20110165236A1 (en) * | 2006-09-22 | 2011-07-07 | Biokey, Inc. | Controlled release hydrogel formulation |
| US20080075785A1 (en) * | 2006-09-22 | 2008-03-27 | San-Laung Chow | Controlled release hydrogel formulation |
| WO2008089103A2 (en) | 2007-01-12 | 2008-07-24 | University Of Maryland, Baltimore | Targeting ncca-atp channel for organ protection following ischemic episode |
| WO2008098160A1 (en) * | 2007-02-09 | 2008-08-14 | University Of Maryland, Baltimore | Antagonists of a non-selective cation channel in neural cells |
| CA3065983C (en) | 2007-06-22 | 2022-07-26 | The United States Of America As Represented By The Department Of Veterans Affairs | Inhibitors of ncca-atp channels for therapy |
| JP2010168301A (ja) * | 2009-01-22 | 2010-08-05 | Kitasato Institute | 中枢循環改善薬 |
| CN103372013A (zh) * | 2013-06-28 | 2013-10-30 | 上海交通大学医学院附属瑞金医院 | 米力农在制备治疗糖尿病足溃疡药物方面的应用 |
| WO2015148684A2 (en) * | 2014-03-26 | 2015-10-01 | Gutierrez Enrique G | Compositions and related methods for treating and preventing viral and retroviral infections |
| US11260074B2 (en) | 2014-03-26 | 2022-03-01 | Enrique G. Gutierrez | Compositions and related methods for reconstituting the immune system of a subject |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859037A (en) * | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
-
2001
- 2001-03-30 AT AT01303020T patent/ATE266409T1/de not_active IP Right Cessation
- 2001-03-30 EP EP01303020A patent/EP1145717B1/de not_active Expired - Lifetime
- 2001-03-30 DK DK01303020T patent/DK1145717T3/da active
- 2001-03-30 TR TR2004/01145T patent/TR200401145T4/xx unknown
- 2001-03-30 ES ES01303020T patent/ES2218338T3/es not_active Expired - Lifetime
- 2001-03-30 DE DE60103203T patent/DE60103203T2/de not_active Expired - Fee Related
- 2001-03-30 PT PT01303020T patent/PT1145717E/pt unknown
- 2001-04-10 US US09/829,874 patent/US6610746B2/en not_active Expired - Fee Related
- 2001-04-11 MX MXPA01003853A patent/MXPA01003853A/es unknown
- 2001-04-11 CA CA002343850A patent/CA2343850A1/en not_active Abandoned
- 2001-04-11 BR BR0101461-7A patent/BR0101461A/pt not_active IP Right Cessation
- 2001-04-13 JP JP2001115674A patent/JP2001354568A/ja active Pending
-
2003
- 2003-06-05 US US10/456,371 patent/US20030216294A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE60103203D1 (de) | 2004-06-17 |
| PT1145717E (pt) | 2004-08-31 |
| MXPA01003853A (es) | 2005-06-30 |
| JP2001354568A (ja) | 2001-12-25 |
| EP1145717A2 (de) | 2001-10-17 |
| CA2343850A1 (en) | 2001-10-13 |
| TR200401145T4 (tr) | 2004-07-21 |
| DE60103203T2 (de) | 2005-05-04 |
| DK1145717T3 (da) | 2004-08-02 |
| ES2218338T3 (es) | 2004-11-16 |
| US6610746B2 (en) | 2003-08-26 |
| EP1145717B1 (de) | 2004-05-12 |
| US20030216294A1 (en) | 2003-11-20 |
| BR0101461A (pt) | 2001-11-13 |
| US20020013268A1 (en) | 2002-01-31 |
| EP1145717A3 (de) | 2002-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60103203D1 (de) | Synergistische Wirkung von Glyburide und Milrinone | |
| CA2474578A1 (en) | Novel pyridin- and pyrimidin-derivatives | |
| DE69213892D1 (de) | Aromatische Aminoalkoholderivate mit antidiabetischer und Antiobesitäts-Wirkung, ihre Herstellung und therapeutische Verwendung | |
| BR0212023A (pt) | Composto, composições e método para controle de pragas invertebradas | |
| PE83199A1 (es) | Composicion farmaceutica de tiazolidinadiona y biguanida para el tratamiento de la diabetes | |
| WO2001082916A3 (en) | Combination therapeutic compositions and methods of use | |
| IL118474A0 (en) | Benzimidazole derivatives pharmaceutical compositions containing the same and the use thereof | |
| BR0107901A (pt) | Composto, composição farmacêutica, método para o trtamento de enfermidade, para o trtamento e/ou prevenção de condições mediadas por receptores nucleares, e para o tratamento e/ou prevenção de diabetes e/ou obesidade, uso de um composto, e, método para tratar diabetes de tipo i, diabetes de tipo ii, tolerância à gligose prejudicada, resistência à insulina ou obesidade | |
| EP1609798A4 (de) | Kondensiertes heterocyclisches derivat, dieses enthaltende medizinische zusammensetzung und deren medizinische verwendung | |
| MY136581A (en) | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | |
| BR0213539A (pt) | Compostos, processo para a preparação de compostos, composições farmacêuticas que compreendem um composto método para o tratamento e/ou profilaxia de enfermidades que estão associadas com dpp iv e utilização desses compostos | |
| BR0209468A (pt) | Composto ou sais ou solvatos deste farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada pelo hppar | |
| BR0211414A (pt) | Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e de diabetes tipo i, diabetes tipo ii, tolerância à glicose, resistência à insulina ou obesidade prejudicadas | |
| AR011829A1 (es) | Combinaciones para diabetes de sulfonilurea-glitazona. | |
| WO2007023507A3 (en) | Oxazolidinones bearing antimicrobial activity composition and methods of preparation | |
| BR0314335A (pt) | Composto, uso do mesmo, composição farmacêutica, e métodos para o tratamento e/ou prevenção de condições mediadas por receptores nucleares, e de diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glicose, resistência à insulina ou obesidade | |
| GEP20084490B (en) | Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses thereof | |
| DK1408966T3 (da) | Synergistiske farmaceutiske kombinationer til forebyggelse eller behandling af diabetes | |
| UY25102A1 (es) | Nueva composición para el tratamiento de diabetes mellitus | |
| BR0206552A (pt) | Utilização de pelo menos uma quinoleìna, quinoleìna, e, composição farmacêutica | |
| BR0107902A (pt) | Composto, composição farmacêutica, métodos para o tratamento de doenças, e para o tratamento e/ou prevençao de, condições mediadas por receptores nucleares, e diabetes e/ou obesidade, uso de uim composto, processo para a preparação de um composto, e, método para tratar diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glucose, resistência à insolina ou obesidade | |
| BR0209650A (pt) | Análogos de adenosina para o tratamento da sìndrome de resistência à insulina e da diabetes | |
| ATE518544T1 (de) | Rotbusch-extrakt gegen diabetes | |
| PE89199A1 (es) | Composicion farmaceutica de tiazolidinadiona y un inhibidor de alfa glucosidasa para el tratamiento de la diabetes | |
| BR9913149A (pt) | Derivados de piperazina antidiabéticos, processos para sua preparação e composições contendo os mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1145717 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |